Validation of the breast cancer surveillance consortium model of breast cancer risk

被引:48
|
作者
Tice, Jeffrey A. [1 ]
Bissell, Michael C. S. [6 ]
Miglioretti, Diana L. [6 ,7 ]
Gard, Charlotte C. [8 ]
Rauscher, Garth H. [9 ]
Dabbous, Firas M. [10 ]
Kerlikowske, Karla [2 ,3 ,4 ,5 ]
机构
[1] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, 1545 Divisadero St,Suite 309, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Vet Affairs, Gen Internal Med Sect, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA
[6] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA
[7] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA
[8] New Mexico State Univ, Dept Econ Appl Stat & Int Business, Las Cruces, NM 88003 USA
[9] Univ Illinois, Div Epidemiol & Biostat, Chicago, IL USA
[10] Advocate Hlth Care, Downers Grove, IL USA
关键词
Breast neoplasms; Risk assessment; Breast density; Breast cancer surveillance consortium; Predictive value of tests; ROC curve; WOMEN; PREDICTION; DENSITY; DISEASE;
D O I
10.1007/s10549-019-05167-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeIn order to use a breast cancer prediction model in clinical practice to guide screening and prevention, it must be well calibrated and validated in samples independent from the one used for development. We assessed the accuracy of the breast cancer surveillance consortium (BCSC) model in a racially diverse population followed for up to 10years.MethodsThe BCSC model combines breast density with other risk factors to estimate a woman's 5- and 10-year risk of invasive breast cancer. We validated the model in an independent cohort of 252,997 women in the Chicago area. We evaluated calibration using the ratio of expected to observed (E/O) invasive breast cancers in the cohort and discrimination using the area under the receiver operating characteristic curve (AUROC).ResultsIn an independent cohort of 252,997 women (median age 50 years, 26% non-Hispanic Black), the BCSC model was well calibrated (E/O=0.94, 95% confidence interval [CI] 0.90-0.98), but underestimated the incidence of invasive breast cancer in younger women and in women with low mammographic density. The AUROC was 0.633, similar to that observed in prior validation studies.ConclusionsThe BCSC model is a well-validated risk assessment tool for breast cancer that may be particularly useful when assessing the utility of supplemental screening in women with dense breasts.
引用
收藏
页码:519 / 523
页数:5
相关论文
共 50 条
  • [1] Validation of the breast cancer surveillance consortium model of breast cancer risk
    Jeffrey A. Tice
    Michael C. S. Bissell
    Diana L. Miglioretti
    Charlotte C. Gard
    Garth H. Rauscher
    Firas M. Dabbous
    Karla Kerlikowske
    [J]. Breast Cancer Research and Treatment, 2019, 175 : 519 - 523
  • [2] Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer
    Gard, Charlotte C.
    Tice, Jeffrey A.
    Miglioretti, Diana L.
    Sprague, Brian L.
    Bissell, Michael C. S.
    Henderson, Louise M.
    Kerlikowske, Karla
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (07)
  • [3] The contribution of common breast cancer susceptibility loci to the breast density and breast cancer association and the Breast Cancer Surveillance Consortium (BCSC) risk model
    Vachon, Celine M.
    Pankratz, V. Shane
    Scott, Christopher G.
    Haeberle, Lothar
    Ziv, Elad
    Jensen, Matthew R.
    Brandt, Kathleen R.
    Whaley, Dana H.
    Olson, Janet E.
    Heusinger, Katharina
    Hack, Carolin C.
    Jud, Sebastian M.
    Beckmann, Matthias W.
    Tice, Jeffrey A.
    Purrington, Kristen S.
    Sellers, Thomas A.
    Kerlikowske, Karla
    Fasching, Peter A.
    Couch, Fergus J.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [4] The Breast Cancer Surveillance Consortium Model Accurately Predicts Invasive Breast Cancer Risk Among Women with LCIS
    Eroglu, I.
    Sevilimedu, V.
    King, T.
    Pilewskie, M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S65 - S65
  • [5] Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort
    Braithwaite, Dejana
    Miglioretti, Diana L.
    Zhu, Weiwei
    Demb, Joshua
    Trentham-Dietz, Amy
    Sprague, Brian
    Tice, Jeffrey A.
    Onega, Tracy
    Henderson, Louise M.
    Buist, Diana S. M.
    Ziv, Elad
    Walter, Louise C.
    Kerlikowske, Karla
    [J]. JAMA INTERNAL MEDICINE, 2018, 178 (04) : 494 - 501
  • [6] Overview of the breast cancer surveillance consortium.
    Ballard-Barbash, R
    Barlow, WE
    Buist, DS
    Carney, P
    Cutter, G
    Dignan, M
    Geller, B
    Kerlikowske, K
    Miglioretti, D
    Rosenberg, R
    Taplin, S
    Yabroff, R
    Yankaskas, B
    Weaver, D
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (11) : 1866S - 1867S
  • [7] Upgrade of high-risk breast lesions detected on mammography in the Breast Cancer Surveillance Consortium
    Menes, Tehillah S.
    Rosenberg, Robert
    Balch, Steven
    Jaffer, Shabnam
    Kerlikowske, Karla
    Miglioretti, Diana L.
    [J]. AMERICAN JOURNAL OF SURGERY, 2014, 207 (01): : 24 - 31
  • [8] Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS
    Eroglu, Idil
    Sevilimedu, Varadan
    Park, Anna
    King, Tari A.
    Pilewskie, Melissa L.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2022, 194 (02) : 257 - 264
  • [9] Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS
    Idil Eroglu
    Varadan Sevilimedu
    Anna Park
    Tari A. King
    Melissa L. Pilewskie
    [J]. Breast Cancer Research and Treatment, 2022, 194 : 257 - 264
  • [10] Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium
    Kerlikowske, Karla
    Bissell, Michael C. S.
    Sprague, Brian L.
    Buist, Diana S. M.
    Henderson, Louise M.
    Lee, Janie M.
    Miglioretti, Diana L.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (07) : 909 - 916